SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila gets USFDA’s nod for Tiadylt ER Capsules, Azelastine Hydrochloride Nasal Spray

16 Aug 2017 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Tiadylt ER (Diltiazem Hydrochloride Extended-Release, USP) Capsules, in strengths of 120 mg, 180 mg, 240 mg, 300 mg, 360 mg and 420 mg. Tiadylt ER capsules are used to treat hypertension (high blood pressure), angina (chest pain), and certain heart rhythm disorders. The drug will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ, Ahmedabad.

The group also received the final approval from the USFDA to market Azelastine Hydrochloride Nasal Spray, 137 mcg. Azelastine Hydrochloride is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing and post-nasal drip caused by allergies or other conditions. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

942.55 0.00 (0.00%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×